Just a spoonful of metformin helps the medicine go down
Diffuse intrinsic pontine glioma (DIPG) is a devastating brain tumor with a need for novel therapies. So far, monotherapies have failed to prolong survival for these patients, and combinatorial strategies have often shown severe, dose-limiting toxicities. In this issue of the JCI, Duchatel, Jackson, and colleagues address this challenge by introducing a drug combination that mitigates side effects and overcomes resistance. After identifying the PI3K/mTOR pathway as a therapeutic vulnerability, they treated DIPG-bearing mice with paxalisib and saw responses but also observed hyperglycemia as a severe side effect. Combining paxalisib with metformin mitigated this toxicity, but also upregulated protein kinase C (PKC) signaling. To tackle this mechanism of resistance, the authors added the PKC inhibitor enzastaurin to their drug combination and showed that this triple therapy led to improved survival. This approach paves the way for improved outcomes for patients with DIPG and other brain tumors.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:134 |
---|---|
Enthalten in: |
The Journal of clinical investigation - 134(2024), 6 vom: 15. März |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Tzaridis, Theophilos [VerfasserIn] |
---|
Links: |
---|
Themen: |
9100L32L2N |
---|
Anmerkungen: |
Date Completed 18.03.2024 Date Revised 18.03.2024 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.1172/JCI179144 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM369776933 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM369776933 | ||
003 | DE-627 | ||
005 | 20240318234832.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240315s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1172/JCI179144 |2 doi | |
028 | 5 | 2 | |a pubmed24n1335.xml |
035 | |a (DE-627)NLM369776933 | ||
035 | |a (NLM)38488006 | ||
035 | |a (PII)e179144 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Tzaridis, Theophilos |e verfasserin |4 aut | |
245 | 1 | 0 | |a Just a spoonful of metformin helps the medicine go down |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 18.03.2024 | ||
500 | |a Date Revised 18.03.2024 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Diffuse intrinsic pontine glioma (DIPG) is a devastating brain tumor with a need for novel therapies. So far, monotherapies have failed to prolong survival for these patients, and combinatorial strategies have often shown severe, dose-limiting toxicities. In this issue of the JCI, Duchatel, Jackson, and colleagues address this challenge by introducing a drug combination that mitigates side effects and overcomes resistance. After identifying the PI3K/mTOR pathway as a therapeutic vulnerability, they treated DIPG-bearing mice with paxalisib and saw responses but also observed hyperglycemia as a severe side effect. Combining paxalisib with metformin mitigated this toxicity, but also upregulated protein kinase C (PKC) signaling. To tackle this mechanism of resistance, the authors added the PKC inhibitor enzastaurin to their drug combination and showed that this triple therapy led to improved survival. This approach paves the way for improved outcomes for patients with DIPG and other brain tumors | ||
650 | 4 | |a Journal Article | |
650 | 7 | |a Metformin |2 NLM | |
650 | 7 | |a 9100L32L2N |2 NLM | |
650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
650 | 7 | |a Drug Combinations |2 NLM | |
700 | 1 | |a Wechsler-Reya, Robert J |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t The Journal of clinical investigation |d 1924 |g 134(2024), 6 vom: 15. März |w (DE-627)NLM000005487 |x 1558-8238 |7 nnns |
773 | 1 | 8 | |g volume:134 |g year:2024 |g number:6 |g day:15 |g month:03 |
856 | 4 | 0 | |u http://dx.doi.org/10.1172/JCI179144 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 134 |j 2024 |e 6 |b 15 |c 03 |